|
LONDON, April 27, 2012 /PRNewswire/ --
On Thursday morning [26 April 2012], David Brenna, chief executive of pharmaceutical giant AstraZeneca, announced his retirement following investor discontent at the company's poor performance.
Below, we look at AstraZeneca's recent decline and how... |